12/23
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
07:04 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
12/19
04:01 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
11/25
08:14 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
01:23 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:12 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:59 am
acrs
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/29
07:30 am
acrs
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
10/20
08:08 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
10/12
12:08 pm
acrs
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? [Yahoo! Finance]
Low
Report
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? [Yahoo! Finance]
10/3
02:37 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
07:00 am
acrs
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Low
Report
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025